7HUANG CK, CHEN YS, LEE SS, et al. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections[J]. J Microbiol Immunol infect, 2002,35 (3) : 159-167.
8WUST J, FREI R. Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of Gram-positive and Gram-negative bacteria from hospitalized patients in Switzerland[J]. Clin Microbiol Infect, 1999,5(5):262-269.
9PFALLER MA, KORTEN V, JONES RN, et al. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the Etest method [J]. Diagn Microbiol Infect Dis, 1999,35(9) :65-73.
10YAMAGUCHI K, MATHAI D, BIEDENBACH DJ, et al. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrubial agents tested against over 2000 clinical isolates from 22 medical centers in Japan [J]. Diagn Microbiol infect Dis,1999,34(2): 123-134.
7Moe S M, Sprague S M. Uremic encephalopathy[ J~. Clin Nephrol, 1994,42(4) :251-256.
8Schmidt P, Musshoff F, Hilgers C, et al. Brain amino acid abnormalities in kidney disease and diabetes mellltus [ J]. Forensic Sci Int, 2004,142( 2-3 ) :221-227.
9Sugimoto M, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA (A) receptor blockade in con- vulsions induced by cephalosporins [ J ]. Neuropharmacol-ogy, 2003,45(3) :304-314.
